Last update 08 May 2025

Adir SRL

Subsidiary Company|1980|France

Overview

Basic Info

Introduction
Adir, a subsidiary of Servier SAS, is an organization based in Suresnes, France that specializes in biological research and development.

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Small molecule drug
Monoclonal antibody
Enzyme

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms8
Hemic and Lymphatic Diseases5
Immune System Diseases3
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug3
Monoclonal antibody3
Enzyme1
Universal CAR-T1
Top 5 TargetCount
ASN(Asparagine)1
NKG2A(killer cell lectin like receptor C1)1
TYMP x TYMS1
CD19(B-lymphocyte antigen CD19)1
IL-7Rα(Interleukin-7 receptor subunit alpha)1

Related

19
Drugs associated with Adir SRL
Calaspargase Pegol-MKNL(Shire Plc)
Target
ASN
Mechanism
ASN inhibitors
Active Org.
Servier Pharmaceuticals LLCServier Pharmaceuticals LLC
 [+6]
Originator Org.
Shire PlcShire Plc
Active Indication
Acute Lymphoblastic Leukemia [+9]
Inactive Indication
Pancreatic Ductal Carcinoma [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date20 Dec 2018
Tipiracil Hydrochloride/Trifluridine
Target
TYMP x TYMS
Mechanism
TYMP inhibitors [+1]
Active Org.
Les Laboratoires Servier SASLes Laboratoires Servier SAS [+9]
Originator Org.
Taiho Pharmaceutical Co., Ltd.Taiho Pharmaceutical Co., Ltd.
Active Indication
HER2-positive gastric cancer [+22]
Inactive Indication
Advanced Gastric Adenocarcinoma [+14]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date24 Mar 2014
Pegaspargase
Target
ASN
Mechanism
ASN inhibitors
Active Org.
Baxalta Canada Corp.
 [+5]
Originator Org.
Enzon Pharmaceuticals, Inc.Enzon Pharmaceuticals, Inc.
Active Indication
Lymphoma [+5]
Inactive Indication
Non-Hodgkin Lymphoma [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date01 Feb 1994
38
Clinical Trials associated with Adir SRL
NCT05312372
/ WithdrawnPhase 1/2IIT
A Phase 1/2, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antineoplastic Activity of S095033 (MAT2A Inhibitor) in Combination With Paclitaxel in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
NCT06079151
/ RecruitingNot Applicable
Physiological Evaluation of the Hemodynamic Effects of Nasal High Flow in Patients Being Explored by Right Heart Catheterisation and Echocardiography for Suspected or Followed Precapillary Pulmonary Hypertension
NCT05638334
/ TerminatedPhase 1IIT
An Open Label, Multicentre, Positron Emission Tomography (PET) Imaging Study Using Zirconium-89 to Investigate the Biodistribution and Tumour Uptake of a PD-L1x4-1BB Bispecific Antibody (S095012) in Patients With Advanced Solid Tumours
100 Clinical Results associated with Adir SRL
Login to view more data
0 Patents (Medical) associated with Adir SRL
Login to view more data
100 Deals associated with Adir SRL
Login to view more data
100 Translational Medicine associated with Adir SRL
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
3
3
Phase 2 Clinical
Phase 3 Clinical
2
11
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free